RECRUITING

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

Description

The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).

Conditions

Advanced Solid Tumors
Talk to us

Related Conditions:

Advanced Solid Tumors

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).

A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants With Advanced Solid Malignancies

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

Condition
Advanced Solid Tumors
Intervention / Treatment

-

Contacts and Locations

Tucson

Local Institution - 0003, Tucson, Arizona, United States, 85716

Los Angeles

Local Institution - 0007, Los Angeles, California, United States, 90033

Aurora

Local Institution - 0014, Aurora, Colorado, United States, 80045

Aurora

Local Institution - 0018, Aurora, Colorado, United States, 80045

Grand Rapids

START Midwest, Grand Rapids, Michigan, United States, 49546

Sioux Falls

Local Institution - 0004, Sioux Falls, South Dakota, United States, 57104

San Antonio

NEXT Oncology, San Antonio, Texas, United States, 78229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN).
  • * Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).
  • * Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
  • * History of or with active interstitial lung disease or pulmonary fibrosis.
  • * Active, known, or suspected autoimmune disease.
  • * Serious uncontrolled medical disorders.
  • * New onset, non-catheter-associated venous thromboembolism within the past 6 months.
  • * Other protocol-defined Inclusion/Exclusion criteria apply.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Bristol-Myers Squibb,

Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

2027-10-14